Related Post
- MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - November 20th, 2024
- Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings - November 20th, 2024
- Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities - November 20th, 2024
- Synata Bio’s Sylonto Project Awarded $4.5 Million NDRC Grant - November 20th, 2024
- Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer - November 20th, 2024
- Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies - November 20th, 2024
- Conquer the New MJBizCon Expo Floor, One Pavilion at a Time - November 20th, 2024
- Helio Genomics to Host Virtual KOL Event to Discuss Recent CLiMB Trial Data and Methylation Model Score in Patients with Hepatocellular Carcinoma... - November 20th, 2024
- TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference - November 20th, 2024
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - November 20th, 2024
- Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation - November 20th, 2024
- Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ - November 20th, 2024
- Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - November 20th, 2024
- Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors - November 20th, 2024
- Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - November 20th, 2024
- Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program - November 20th, 2024
- Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance... - November 20th, 2024
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - November 20th, 2024
- Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS - November 20th, 2024
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - November 20th, 2024
- MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia - November 18th, 2024
- Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer - November 18th, 2024
- Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on... - November 18th, 2024
- EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome - November 18th, 2024
- genXtraits Inc. licenses Fulcrum™ toolkit from Pairwise to enable its technology platform for generation of high-value enhanced crops with dominant... - November 18th, 2024
- Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - November 18th, 2024
- Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning... - November 18th, 2024
- Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit - November 18th, 2024
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - November 18th, 2024
- Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 18th, 2024
- Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - November 18th, 2024
- Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer - November 18th, 2024
- Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the... - November 18th, 2024
- Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - November 18th, 2024
- Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease - November 18th, 2024
- Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease - November 18th, 2024
- Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM... - November 18th, 2024
- Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA - November 18th, 2024
- Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List - November 18th, 2024
- PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" - November 18th, 2024
- AssistRx Joins Inaugural Drug Channels Leadership Forum as Diamond Sponsor - November 12th, 2024
- Collegium to Participate in Upcoming Investor Conferences - November 12th, 2024
- Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem - November 12th, 2024
- Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer - November 12th, 2024
- Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA) - November 12th, 2024
- Nkarta to Participate in an Upcoming Investor Conference - November 12th, 2024
- Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - November 12th, 2024
- Vosita Announces New Features and Exciting Giveaway - November 12th, 2024
- Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual... - November 12th, 2024
- Mustang Bio Receives Positive Listing Determination from Nasdaq - November 12th, 2024
- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq - November 12th, 2024
- Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business - November 12th, 2024
- Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product... - November 12th, 2024
- Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting - November 12th, 2024
- Vincerx Pharma Reports Third Quarter 2024 Financial Results - November 12th, 2024
- Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - November 12th, 2024
- Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - November 12th, 2024
- SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - November 12th, 2024
- Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000 - November 12th, 2024
- Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) - November 10th, 2024
- CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - November 10th, 2024
- Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024 - November 10th, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 - November 10th, 2024
- Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for... - November 10th, 2024
- Ardelyx Responds to District Court Decision Granting Motion to Dismiss - November 10th, 2024
- Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid... - November 10th, 2024
- Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the... - November 10th, 2024
- Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued... - November 10th, 2024
- Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting - November 10th, 2024
- Aptose Reports Results for the Third Quarter 2024 - November 10th, 2024
- PacBio to Present at Upcoming Investor Conferences - November 10th, 2024
- Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - November 10th, 2024
- Teva to Present at the Jefferies London Healthcare Conference - November 10th, 2024
- Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - November 10th, 2024
- Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates... - November 10th, 2024
- Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the... - November 10th, 2024
- InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10th, 2024
- Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid... - November 10th, 2024
- Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration... - November 10th, 2024
- Rani Therapeutics to Participate in Upcoming Investor Conferences - November 8th, 2024
Recent Comments